A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion

Key Points

• Tenecteplase did not lead to greater vision recovery compared to aspirin, emphasizing effectiveness concerns.
• At 30 days, outcomes did not significantly differ between the two treatments, raising questions about intervention.
• Intravenous tenecteplase administered within 4.5 hours failed to produce expected benefits in visual outcomes.
• Serious safety concerns associated with tenecteplase treatment suggest the need for cautious application.

Abstract